北京大学第一医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 肝细胞癌Hepatocellular carcinoma19 篇牵头论文牵头 2 项开放试验
- 胃癌Stomach cancer27 篇牵头论文牵头 1 项开放试验
- 肝母细胞瘤Hepatoblastoma0 篇牵头论文
- 骨肉瘤Osteosarcoma4 篇牵头论文牵头 1 项开放试验
- 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
- 神经母细胞瘤Neuroblastoma6 篇牵头论文
- 尤文肉瘤Ewing sarcoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma17 篇牵头论文牵头 5 项开放试验
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis1 篇牵头论文
- 血友病 AHaemophilia A1 篇牵头论文
- 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome2 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder1 篇牵头论文
- IgG4相关性疾病IgG4-related disease5 篇牵头论文
- 重症肌无力Myasthenia gravis3 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 肝包虫病Hepatic echinococcosis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis2 篇牵头论文
- 脊髓性肌萎缩症Spinal muscular atrophy1 篇牵头论文
- 法布雷病Fabry disease8 篇牵头论文
- 庞贝病Pompe disease1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy11 篇牵头论文
- 白塞病Behçet disease2 篇牵头论文
- Alport 综合征Alport syndrome8 篇牵头论文
- IgA 肾病IgA nephropathy65 篇牵头论文牵头 1 项开放试验
- 尼曼-匹克病 C 型Niemann–Pick disease type C0 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
- 先天性巨结肠Hirschsprung disease1 篇牵头论文
- 遗传性大疱性表皮松解症Inherited epidermolysis bullosa5 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、视网膜母细胞瘤、脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、血栓性血小板减少性紫癜、范可尼贫血、烟雾病、肝豆状核变性、胆道闭锁、肺淋巴管平滑肌瘤病、戈谢病、成骨不全症、先天性膈疝、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 19 篇,占 0.1%。
北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 分期
- 不分期
- 开始
- 2026-04
- 登记号
- NCT07557225
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学第一医院北京
- 正在招募GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
- 分期
- 不分期
- 开始
- 2026-08
- 登记号
- NCT07795437
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学第一医院北京
- 正在招募DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
- 分期
- 不分期
- 开始
- 2023-12
- 登记号
- NCT06190665
年龄 18 岁 至 80 岁(登记的条件)
牵头:东南大学附属中大医院;另有 1 家列出的医院为研究中心北京、南京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文19
- Impact of altitude on hemoglobin dynamics and prognosis in patients with advanced hepatocellular carcinoma receiving antiangiogenic TKIs: A propensity score matched study.
- Baseline FIB-4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV-Related Small HCC.
- Radiofrequency ablation with or without conventional transarterial chemoembolization for subcapsular versus nonsubcapsular hepatocellular carcinoma within Milan criteria: a propensity score-matched study.
- Feasibility of novel intraoperative navigation for anatomical liver resection using real-time virtual sonography combined with indocyanine green fluorescent imaging technology.
- No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy.
- Which is more appropriate for the evaluation of HCC, RECIST or mRECIST criteria?
- Letter to the editor regarding "Comparing long-term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial chemoembolization: A propensity score matched study".
- HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation.
- Methodological challenges in studying immune-suppressive neutrophils in HCC models.
- Letter to the editor Re "Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study".
- Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.
- A case report of situs inversus totalis undergoing multiple interventional strategies.
- Loadability and Releasing Profiles In Vitro and Pharmacokinetics In Vivo of Vinorelbine and Raltitrexed by CalliSpheres Beads.
- Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment.
- Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art.
- Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance.
- Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
- Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.
- Genome-wide association study identifies new loci associated with risk of HBV infection and disease progression.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.3%。
北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- 分期
- 未注明
- 开始
- 2026-09
- 登记号
- NCT07039474
年龄 18 岁 至 75 岁(登记的条件)
牵头:北京大学第一医院北京
- 正在招募A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- 分期
- II期
- 开始
- 2025-02
- 登记号
- NCT06760819
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、北京、杭州、长沙
- 正在招募Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- 分期
- 未注明
- 开始
- 2025-02
- 登记号
- NCT06846996
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春
- 正在招募Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
- 分期
- 不分期
- 开始
- 2025-10
- 登记号
- NCT07175155
年龄 18 岁 至 未注明(登记的条件)
牵头:浙江大学医学院附属第一医院;另有 2 家列出的医院为研究中心北京、台州、杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文27
- Effectiveness of the aspiration method in preventing delayed bleeding after gastric endoscopic submucosal dissection.
- Rapid and specific immunoPET imaging of Nectin-4 in gastric cancer and non-small cell lung cancer using [64Cu]Cu-NOTA-EV-F(ab')2.
- Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.
- Noninvasive Evaluation of Trop2 Expression Using 64Cu-NOTA-Trodelvy-F(ab')2 in Gastric and Pancreatic Cancer.
- ImmunoPET Imaging of Nectin4 Expression in Gastric and Bladder Cancer Using [64Cu]Cu-NOTA-Padcev.
- Prognostic value of neutrophil-lymphocyte ratio in gastroenteropancreatic neuroendocrine neoplasm: a systematic review and meta-analysis.
- Evaluating the efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced gastric cancer undergoing radical gastrectomy: a retrospective study.
- Gastric metastasis from ovarian carcinoma diagnosed by EUS-FNB: A case report.
- A solitary polyp of the stomach.
- Cross-talk between Helicobacter pylori and gastric cancer: a scientometric analysis.
- Comparison of nasojejunal nutrition and intravenous nutrition supplementation in patients with upper gastrointestinal tract strictures and analysis of risk factors for malnutrition.
- Plasma metabolomics and lipidomics reveal potential novel biomarkers in early gastric cancer: An explorative study.
- Short-and long-term outcomes of one-stage versus two-stage gastrectomy for perforated gastric cancer: a multicenter retrospective propensity score-matched study.
- LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing.
- Palliative Gastrectomy Improves the Survival of Patients with Metastatic Early-Onset Gastric Cancer: A Retrospective Cohort Study.
- A novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer.
- The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.
- A convolutional neural network-based system for detecting early gastric cancer in white-light endoscopy.
- LncRNA CRART16/miR-122-5p/FOS axis promotes angiogenesis of gastric cancer by upregulating VEGFD expression.
- Value of Preoperative Hematological Parameters in the Prognosis of Gastric Cancer Patients Undergoing a Total Gastrectomy.
- CAF promotes chemoresistance through NRP2 in gastric cancer.
- Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma.
- Survival benefits from neoadjuvant treatment in gastric cancer: a systematic review and meta-analysis.
- Multivisceral resection for locally advanced gastric cancer: A retrospective study.
- SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis.
- An investigation on gastric cancer staging using CT structured report.
- MiR-205-5p suppresses angiogenesis in gastric cancer by downregulating the expression of VEGFA and FGF1.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial
- Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis
- Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年没有牵头肝母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 9 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
- 分期
- 早期I期
- 开始
- 2026-04
- 登记号
- NCT07774533
年龄 10 岁 至 80 岁(登记的条件)
牵头:北京大学第一医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文4
- pH-responsive paclitaxel prodrug encapsulated in a polypeptide-chitosan polymer delivery system for osteosarcoma treatment.
- Primary ewing sarcoma in the uterine cervix with multiple bone metastases.
- The expression of hydrogen sulfide-producing enzymes in primary and lung metastatic osteosarcoma.
- Cisplatin-resistant osteosarcoma cell-derived exosomes confer cisplatin resistance to recipient cells in an exosomal circ_103801-dependent manner.
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- 分期
- II期
- 开始
- 2021-08
- 登记号
- NCT04924075
年龄 12 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文6
- Tamibarotene promotes differentiation of neuroblastoma SH-SY5Y cells into neurons, which is associated with activation of the PI3K/AKT signaling pathway.
- Bexarotene Promotes Neuroblastoma SH-SY5Y Cell Differentiation to Mature Neurons with Decreased Proliferation.
- Pathologic changes in neuronal intranuclear inclusion disease are linked to aberrant FUS interaction under hyperosmotic stress.
- In Vitro Effects of Acitretin on Human Neuronal SH-SY5Y Cells.
- Transcriptome Analysis Reveals the Anti-Tumor Mechanism of Eucalyptol Treatment on Neuroblastoma Cell Line SH-SY5Y.
- Neuroblastoma SH-SY5Y Cell Differentiation to Mature Neuron by AM580 Treatment.
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
- 分期
- I期
- 开始
- 2025-05
- 登记号
- NCT06926283
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、杭州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 17 篇,占 1.0%。
北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 11
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
- 分期
- I期
- 开始
- 2026-06
- 登记号
- NCT07660939
年龄 18 岁 至 80 岁(登记的条件)
牵头:北京大学第一医院北京
- 正在招募A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
- 分期
- 早期I期
- 开始
- 2025-04
- 登记号
- NCT06717113
年龄 18 岁 至 80 岁(登记的条件)
牵头:北京大学第一医院北京
- 正在招募68Ga-BCMA PET/CT in Multiple Myeloma
- 分期
- II/III期
- 开始
- 2025-12
- 登记号
- NCT07319897
年龄 18 岁 至 80 岁(登记的条件)
牵头:北京大学第一医院;另有 2 家列出的医院为研究中心北京、石家庄、长春
- 正在招募PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
- 分期
- 早期I期
- 开始
- 2024-04
- 登记号
- NCT06385652
年龄 18 岁 至 90 岁(登记的条件)
牵头:北京大学第一医院北京
- 正在招募A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
- 分期
- 未注明
- 开始
- 2021-07
- 登记号
- NCT05283993
年龄未注明(登记的条件)
牵头:北京大学第一医院北京
- 正在招募A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-02
- 登记号
- NCT07258511
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-05
- 登记号
- NCT07518186
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春
- 正在招募Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- 分期
- 未注明
- 开始
- 2024-12
- 登记号
- NCT07028970
年龄未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、武汉、郑州
- 正在招募Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- 分期
- III期
- 开始
- 2022-09
- 登记号
- NCT05243797
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春
- 正在招募A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- 分期
- III期
- 开始
- 2022-10
- 登记号
- NCT05552222
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文17
- Metabolomics and machine learning approaches for diagnostic biomarkers screening in systemic light chain amyloidosis.
- CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.
- B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study.
- Development and Preclinical Validation of a Novel 89Zr-Labeled BCMA-Targeting Antibody for ImmunoPET Imaging: Application in Multiple Myeloma Models and First-In-Nonhuman-Primates.
- Pharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted 68Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study.
- 5-Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma.
- Development of a Novel Peptide-Based PET Tracer [68Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma.
- Identification of CD8+ T-cell epitope from multiple myeloma-specific antigen AKAP4.
- Prognostic Factors of AL-PCMM and AL-MM: A Single-Center Retrospective Study.
- Clinical Characteristics and Prognosis of Multiple Myeloma With Myelomatous Pleural Effusion: A Retrospective Single-Center Study.
- Myeloma cast nephropathy with diffuse amyloid casts without systemic amyloidosis: two cases report.
- Crystalline appearance in light chain cast nephropathy is associated with higher early mortality in patients with newly diagnosed multiple myeloma.
- Coexistent light chain deposition disease, light chain cast nephropathy, and vascular light chain amyloidosis in a patient with IgD lambda multiple myeloma.
- Contradictory Phenomenon Between Serum Separator Tube and Plasma Tube: A Case Report.
- Crystals in myeloma cast nephropathy.
- Crystalline light chain cast nephropathy in multiple myeloma.
- C3 glomerulonephritis along with light chain proximal tubulopathy without crystal deposits in multiple myeloma: a case report.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
- GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
- A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
- 68Ga-BCMA PET/CT in Multiple Myeloma
- PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
- A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
- A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Daratumumab
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
这些数字背后的记录
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
血液疾病
非典型溶血性尿毒症综合征
Atypical haemolytic uraemic syndrome2021–2025 年中国大陆作者发表的 27 篇非典型溶血性尿毒症综合征 PubMed 英文论文中,这家医院牵头了 2 篇,占 7.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 6 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)3
- Genetic and functional analysis of two missense mutations in CD46 predispose to postpartum atypical hemolytic uremic syndrome.
- Complement Activation in Progression of Chronic Kidney Disease.
- Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- 分期
- II/III期
- 开始
- 2024-07
- 登记号
- NCT06413654
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 2.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。
这些数字背后的记录
牵头的论文5
- Case Report: A rare case of concurrence of IgG4-related tubulointerstitial nephritis and renal Amyloid A amyloidosis.
- IgG4-related disease presenting with retroperitoneal fibrosis and hypertrophic spinal pachymeningitis: a rare case report and literature review.
- IgG4-related eosinophilic pleural effusion: a case report.
- Pancreatic cancer detected with 18F-FDG PET/CT in a case of IgG4-related disease.
- Active IgG4-related disease with bone marrow involvement: a report of 2 cases and case-based review.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 11 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- 分期
- II/III期
- 开始
- 2024-07
- 登记号
- NCT06447597
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 13 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文1
早期论文(2016–2020 年)4
- Cerebrospinal fluid CD20 positive B-cell expansion in a case of anti-NMDAR encephalitis.
- Anesthetic Management of Patients with Anti-N-methyl-D-aspartate Receptor Encephalitis: A Report of Two Cases.
- Anti-N-methyl-d-aspartate receptor encephalitis in a patient with neuromyelitis optica spectrum disorders.
- [Electroencephalographic features of anti-N-methyl-D-aspartate receptor encephalitis in children].
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
肝包虫病
Hepatic echinococcosis2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 6 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文4
- Cellular senescence-related gene signatures in idiopathic pulmonary fibrosis: insights from bioinformatics.
- Overexpression of KLF4 Suppresses Pulmonary Fibrosis through the HIF-1α/Endoplasmic Reticulum Stress Signaling Pathway.
- Patterns of Interstitial Lung Disease and Prognosis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Pulmonary tuberculosis associated acute fibrinous and organizing pneumonia: A case report and literature review.
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 8 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- 分期
- I/II期
- 开始
- 2026-07
- 登记号
- NCT07554924
年龄 未注明 至 180 天(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、杭州
- 正在招募Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
- 分期
- III期
- 开始
- 2025-05
- 登记号
- NCT06971094
年龄 2 岁 至 12 岁(登记的条件)
牵头方不是列出的医院;另有 6 家列出的医院为研究中心北京、武汉、深圳、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
- Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
- Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)
- A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
- Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
- Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 8 篇,占 11.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 11 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- 分期
- 未注明
- 开始
- 2025-11
- 登记号
- NCT07187440
年龄 7 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文8
- The vestibular and oculomotor dysfunction in Fabry disease: a cohort study in China.
- Elevated circulating cell-free mitochondrial DNA in fabry disease: insights into inflammatory activation.
- Corneal neuro-immune crosstalk in Fabry disease: An in vivo confocal microscopic study.
- Deep learning assisted retinal microvasculature assessment and cerebral small vessel disease in Fabry disease.
- Inflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy.
- Evaluation of global and regional myocardial work by echocardiography in patients with Fabry disease.
- Investigation of ocular involvement in patients with Fabry disease.
- Brain MRI correlations with disease burden and biomarkers in Fabry disease.
早期论文(2016–2020 年)1
其他疾病
庞贝病
Pompe disease2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 6 家医院列在庞贝病下全国有 30 家医院列在庞贝病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 11 篇,占 5.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
这些数字背后的记录
牵头的论文11
- Interleukin-17B is a new biomarker of human muscle regeneration in dystrophinopathies.
- RNA sequencing facilitates the identification of genetic causes of Duchenne muscular dystrophy and proposes a stepwise DMD diagnostic procedure.
- Single-Nucleus RNA Sequencing Unravels Early Mechanisms of Human Becker Muscular Dystrophy.
- Prevalence of Adeno-Associated Virus-9-Neutralizing Antibody in Chinese Patients with Duchenne Muscular Dystrophy.
- A novel biomarker of fibrofatty replacement in dystrophinopathies identified by integrating transcriptome, magnetic resonance imaging, and pathology data.
- A new pseudoexon activation due to ultrarare branch point formation in Duchenne muscular dystrophy.
- Clinical and genetic interpretation of uncertain DMD missense variants: evidence from mRNA and protein studies.
- Cryptic exon activation caused by a novel deep-intronic splice-altering variant in Becker muscular dystrophy.
- Clinical, muscle imaging, and genetic characteristics of dystrophinopathies with deep-intronic DMD variants.
- Clinical, pathological, and genetic characterization in a large Chinese cohort with female dystrophinopathy.
- Characteristics and feasibility of ambulatory respiratory assessment of paediatric neuromuscular disease: an observational retrospective study.
中文论文(未计入)2
早期论文(2016–2020 年)4
- Long-read whole-genome sequencing for the genetic diagnosis of dystrophinopathies.
- Splicing Characteristics of Dystrophin Pseudoexons and Identification of a Novel Pathogenic Intronic Variant in the DMD Gene.
- T2 Mapping and Fat Quantification of Thigh Muscles in Children with Duchenne Muscular Dystrophy.
- [Magnetic resonance imaging of dystrophinopathy that mimics adductor enthesopathy].
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- 分期
- III期
- 开始
- 2023-11
- 登记号
- NCT06145893
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)1
其他疾病
Alport 综合征
Alport syndrome2021–2025 年中国大陆作者发表的 58 篇Alport 综合征 PubMed 英文论文中,这家医院牵头了 8 篇,占 13.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 7 家医院列在Alport 综合征下全国有 60 家医院列在Alport 综合征下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Alport 综合征开放试验。
这些数字背后的记录
牵头的论文8
- A retrospective study of kidney disease in Alport syndrome during and after pregnancy.
- Characterization of Ocular Morphology in Col4a3-/- Mice as a Murine Model for Alport Syndrome.
- Primary membranous nephropathy in two siblings with one combined with anti-glomerular basement membrane disease: a case report.
- Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients.
- Combined Alport syndrome, Klinefelter syndrome and Fanconi syndrome in a Chinese boy.
- A woman with Alport syndrome in compound-heterozygous state in pregnancy: lessons for the clinical nephrologist.
- Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.
- mRNA analysis identifies deep intronic variants causing Alport syndrome and overcomes the problem of negative results of exome sequencing.
早期论文(2016–2020 年)12
- Reassessing the pathogenicity of c.2858G>T(p.(G953V)) in COL4A5 Gene: report of 19 Chinese families.
- [Clinical phenotype of Alport syndrome in monozygotic twins].
- Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome.
- Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome.
- X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males.
- Urinary epidermal growth factor as a prognostic marker for the progression of Alport syndrome in children.
- Renal, auricular, and ocular outcomes of Alport syndrome and their current management.
- [Detection of large deletions in X linked Alport syndrome using competitive multiplex fluorescence polymerase chain reaction].
- Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.
- Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.
- [Analysis of diagnosis and treatment of Alport syndrome].
- [Clinical and genetic features of X-linked Alport syndrome in men positive for the collagen Ⅳ α5 chain in epidermal basement membrane].
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 65 篇,占 8.8%。
北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
- 分期
- 不分期
- 开始
- 2026-08
- 登记号
- NCT07822100
年龄 18 岁 至 75 岁(登记的条件)
牵头:北京大学第一医院北京
- 正在招募A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
- 分期
- I/II期
- 开始
- 2026-02
- 登记号
- NCT07375758
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07390123
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心Huangshan City、上海、临沂、北京、湛江、芜湖、西安、长春、长沙
- 正在招募A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
- 分期
- II期
- 开始
- 2026-07
- 登记号
- NCT07582133
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
- 分期
- II期
- 开始
- 2026-05
- 登记号
- NCT07614477
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、天津
- 正在招募A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- 分期
- III期
- 开始
- 2025-07
- 登记号
- NCT06963827
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、包头、北京、南京、南昌、南通、厦门、宁波、广州、成都、无锡、杭州、济南、深圳、珠海、长沙
- 正在招募A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
- 分期
- III期
- 开始
- 2025-06
- 登记号
- NCT07014826
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
- 分期
- II期
- 开始
- 2025-08
- 登记号
- NCT07616700
年龄未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
- 分期
- II期
- 开始
- 2023-05
- 登记号
- NCT05775042
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文65
- The Association of Proteinuria Target Achievement Timing and Stability with Adverse Kidney Outcomes among Patients with IgA Nephropathy: A Cohort Study.
- CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy.
- Genetic Determinants of Steroid Responsiveness in IgA Nephropathy.
- New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy.
- Expanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy.
- Red blood cell casts on kidney biopsy and progression of IgA nephropathy.
- Long-term outcomes of IgA nephropathy in China.
- Efficacy and Safety of Telitacicept in IgA Nephropathy: A Retrospective, Multicenter Study.
- Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series.
- Causal relationships between gut microbiota and IgA nephropathy: evidence from Mendelian randomization and microbiome validation.
- Origin of poorly galactosylated IgA1 other than mucosa: a viewpoint from a report on patient with IgA vasculitis.
- The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.
- Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study.
- Clinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study.
- Sunitinib-induced endocapillary proliferative glomerulonephritis with IgA2 deposit in addition to thrombotic microangiopathy: a case report.
- Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by Lactobacillus casei cell wall extract.
- Unveiling biomarkers and therapeutic targets in IgA nephropathy through large-scale blood transcriptome analysis.
- A cluster of type I interferon-regulated genes associates with disease activity and prognosis in patients with IgA nephropathy.
- Circulating Proteins and IgA Nephropathy: A Multiancestry Proteome-Wide Mendelian Randomization Study.
- Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
- Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results.
- Targeted release of budesonide in primary IgA nephropathy.
- Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in IgA nephropathy, an update of current clinical trials.
- Current understanding and new insights in the treatment of IgA nephropathy.
- Association between urinary C4d levels and disease progression in IgA nephropathy.
- Genetics of IgA nephrology: risks, mechanisms, and therapeutic targets.
- Are children with IgA nephropathy different from adult patients?
- Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study.
- The Genetics of IgA Nephropathy: Implications for Future Therapies.
- Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study.
- Mesangial C3 Deposition, Complement-Associated Variant, and Disease Progression in IgA Nephropathy.
- Machine learning in predicting T-score in the Oxford classification system of IgA nephropathy.
- Global trends and hotspots in IgA nephropathy: a bibliometric analysis and knowledge map visualization from 2012 to 2023.
- The spectrum and changes of biopsy-proven kidney diseases in Chinese children.
- Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients.
- MTMR3 risk alleles enhance Toll Like Receptor 9-induced IgA immunity in IgA nephropathy.
- Glucocorticoids for IgA nephropathy-pro.
- Intensive blood pressure control and the progression of IgA nephropathy: a cohort study using marginal structural models.
- Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial.
- Diagnosis and treatment of IgA nephropathy and IgA vasculitis nephritis in Chinese children.
- Urinary epidermal growth factor predicts complete remission of proteinuria in Chinese children with IgA nephropathy.
- The clinical and pathological characteristics of IgA nephropathy patients in Tibet.
- Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome?
- Complement factor H variants are associated with microangiopathy lesions in IgA nephropathy.
- Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
- The effect of immunosuppressive therapy in patients with fibrinoid necrosis lesions in a large cohort of patients with IgA nephropathy.
- Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience.
- The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study.
- The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: a cohort study.
- Clinical and Pathological Features of Renal Presentations in Polycythemia Vera.
- Sustained release of Lactobacillus casei cell wall extract can induce a continuous and stable IgA deposition model.
- Collectin11 and Complement Activation in IgA Nephropathy.
- Poly-IgA Complexes and Disease Severity in IgA Nephropathy.
- Exome Chip Analyses and Genetic Risk for IgA Nephropathy among Han Chinese.
- Potential Roles of Oral Microbiota in the Pathogenesis of Immunoglobin A Nephropathy.
- Complement Activation Is Associated With Crescents in IgA Nephropathy.
- A Functional Variant rs3093023 in CCR6 Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population.
- Immune characteristics of renal allograft donors with mesangial IgA deposition.
- Urinary sediments could differentiate endocapillary proliferative lupus nephritis and endocapillary proliferative IgA nephropathy.
- Interaction between GALNT12 and C1GALT1 Associates with Galactose-Deficient IgA1 and IgA Nephropathy.
- Shared genetic study gives insights into the shared and distinct pathogenic immunity components of IgA nephropathy and SLE.
- O-glycoforms of polymeric immunoglobulin A1 in the plasma of patients with IgA nephropathy are associated with pathological phenotypes.
- Mass spectrometry-based screening identifies circulating immunoglobulinA-α1-microglobulin complex as potential biomarker in immunoglobulin A nephropathy.
- Associations of ABO blood type and galactose-deficient immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy.
- Is IgA nephropathy the same disease in different parts of the world?
中文论文(未计入)5
- [Interpretation of the clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)].
- [The standardization process and clinical challenges in the diagnosis and treatment of IgA nephropathy in China:commentary on the clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis i
- [Immunomodulatory effects and research progresses of budesonide enteric-coated capsules in IgA nephropathy].
- [IgA nephropathy: current treatment status, prospects, opportunities, and challenges].
- [Clinical and genetic analysis of a child with co-morbid progressive IgA nephropathy and COQ8B-associated glomerulopathy].
早期论文(2016–2020 年)29
- Persistent Hematuria and Kidney Disease Progression in IgA Nephropathy: A Cohort Study.
- Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study.
- Neutrophil-to-lymphocyte ratio as an independent inflammatory indicator of poor prognosis in IgA nephropathy.
- MicroRNA-21-5p participates in IgA nephropathy by driving T helper cell polarization.
- Variation in complement factor H affects complement activation in immunoglobulin A vasculitis with nephritis.
- Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.
- Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy.
- [Efficacy and safety of steroid combined with immunosuppressants in the treatment of primary IgA nephropathy in children: a Meta analysis].
- Microangiopathic Lesions in IgA Nephropathy: A Cohort Study.
- Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
- Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.
- [Trans-ethnic analysis of susceptibility variants in IgA nephropathy].
- Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy.
- Autophagy in Immune-Related Renal Disease.
- Urine afamin and afamin-creatinine ratio as biomarkers for kidney injury.
- Insights into the Role of Mucosal Immunity in IgA Nephropathy.
- Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.
- Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy.
- Update on treatment of immunoglobulin A nephropathy.
- Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy.
- Coding and Noncoding Variants in CFH Act Synergistically for Complement Activation in Immunoglobulin A Nephropathy.
- Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
- Mannose-Binding Lectin Levels Could Predict Prognosis in IgA Nephropathy.
- Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy.
- Plasma Exchange as an Adjunctive Therapy for Crescentic IgA Nephropathy.
- Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy.
- Elevated Plasma α-Defensins (HNP1-3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy.
- Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy.
它在 ClinicalTrials.gov 上的全部试验(任何状态)30
- A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy
- Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
- Registry of IgA Nephropathy in Chinese Children
- To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
- Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
- A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
- A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
- Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
- Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
- IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
- Efficacy and Safety Study of HS-10542 for IgA Nephropathy
- A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
- Study of CM313 in Subject With IgA Nephropathy
- A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
- A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
- Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
- Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
- A Phase IIa Study in Primary IgA Nephropathy Patients
- A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- TESTING -ON Post-Trial ObservatioNal Cohort Study
- Atrasentan in Patients With IgA Nephropathy
- A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
其他疾病
尼曼-匹克病 C 型
Niemann–Pick disease type C2021–2025 年没有牵头尼曼-匹克病 C 型的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 3 家医院列在尼曼-匹克病 C 型下全国有 15 家医院列在尼曼-匹克病 C 型下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尼曼-匹克病 C 型开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
中文论文(未计入)2
早期论文(2016–2020 年)3
- Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
- Efficacy of ursodeoxycholic acid combined with prednisolone and immunosuppressant triple therapy in the treatment of refractory primary biliary cholangitis.
- [Is autoimmune cholangitis-anti-mitochondrial antibody-negative primary biliary cholangitis still an independent disease?].
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
这些数字背后的记录
其他疾病
先天性巨结肠
Hirschsprung disease2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 8 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。
其他疾病
遗传性大疱性表皮松解症
Inherited epidermolysis bullosa2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 5 篇,占 8.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 4 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。
这些数字背后的记录
牵头的论文5
- Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study.
- Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib.
- Large intragenic deletion of KRT14 causes autosomal-dominant epidermolysis bullosa simplex with generalized hyperpigmentation.
- KLHL24-Mediated Hair Follicle Stem Cells Structural Disruption Causes Alopecia.
- Epidermolysis Bullosa Pruriginosa Treated With Baricitinib.
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 7 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
联系这家医院
出示给工作人员或司机的院名卡
北京大学第一医院
Peking University First Hospital
北京
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药